NCT04607512View on ClinicalTrials.gov

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Cardiac Safety
Interventions
DRUG

telaglenastat

glutaminase inhibitor

OTHER

telaglenastat placebo

matching placebo for telaglenastat

OTHER

moxifloxicin

positive control

Trial Locations (1)

BT9 6AD

Celerion, Belfast

Sponsors
All Listed Sponsors
lead

Calithera Biosciences, Inc

INDUSTRY